Analystreport

Arbutus Biopharma Co. (NASDAQ: ABUS) had its price target raised by analysts at JMP Securities to $5.00. They now have a "buy" rating on the stock.

Arbutus Biopharma Corporation  (ABUS) 
Last arbutus biopharma corporation earnings: 11/6 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.arbutusbio.com/node/5806